Abstract-Hypertension, an important cause of chronic kidney disease, is characterized by peritubular capillary (PTC) loss.
P eritubular capillary (PTC) damage and rarefaction characterize chronic kidney disease (CKD) and accompany declining renal function in diverse renal disorders. [1] [2] [3] PTC loss has been associated with inappropriate and sustained activation of the peritubular endothelium. 4 The ability to detect PTC injury noninvasively could allow monitoring of renal disease progression. However, to date, there is no method to assess noninvasively PTC dropout in human subjects.
Extracellular vesicles (EVs) are membrane-bound vesicles produced and released by cells under duress and are classified as exosomes, microparticles, or apoptotic bodies depending on their origin, size, and content. 5 Within the kidney, EVs can originate from diverse cell types, such as podocytes, tubular epithelial cells, or endothelial cells, and changes in the numbers or characteristics of EVs may be associated with development of disease. 6 Therefore, levels of urinary EVs have been used as biomarkers in various kidney disorders, including acute kidney injury, 7 polycystic kidney disease, 8 and glomerular diseases. 9 We have previously shown that urine of hypertensive patients contains EVs reflecting podocyte injury and differential expression of microRNA. 10, 11 However, EVs reflecting endothelial damage of PTC have not been identified.
Endothelial microparticles (EMPs) are EVs that are shed by the endothelium as a result of activation, injury, or apoptosis of endothelial cells and are considered important biomarkers of the status of endothelial cells and vascular function. 12, 13 Thus, levels of EMPs are increased in microvascular diseases with endothelial injury.
14 CD31 and CD144 are endothelial markers [15] [16] [17] but can also be expressed on platelets, neutrophils, lymphocyte subset, and hematopoietic stem cells.
14,18-20 PL-VAP (plasmalemmalvesicle-associated protein) is expressed on the vascular endothelium of various organs, predominantly in the lung, kidney, spleen, endocrine glands, and digestive tract. 21 In the human kidney, PL-VAP is abundantly expressed in the endothelium of PTC and vasa recta but is undetectable in glomerular and arterial endothelium. 22, 23 Hence, urinary EVs expressing PL-VAP likely originate from PTC or vasa recta endothelium.
Hypertension may lead to renal injury and capillary loss, but these are difficult to detect in the intact kidney. Thus, the purpose of this study was to test the hypothesis that PTC-EMPs would be increased in patients with essential (EH) and renovascular (RVH) hypertension compared with healthy volunteers (HVs) and correlate with indices of renal function.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Patient Selection
We prospectively enrolled 38 hypertensive patients ≥18 years of age with EH (n=14) or RVH (n=24) and with relatively preserved renal function to participate in the studies. Atherosclerotic renal artery stenosis was defined as cross-sectional luminal obstruction >60% as per computed tomography (CT; Figure 1A ) or magnetic resonance angiography or by Doppler velocities ≥300 cm/s. Exclusion criteria included serum creatinine >2.5 mg/dL, diabetes mellitus, recent cardiovascular events (myocardial infarction, stroke, or congestive heart failure) within the past 6 months, fibromuscular dysplasia, pregnancy, and kidney transplant. Normotensive HVs (systolic blood pressure [BP] <130 mm Hg and diastolic BP <80 mm Hg) were prospectively recruited through the Mayo Clinic Biobank and matched to patients with EH and RVH according to age and body mass index. This study was approved by the institutional review board of the Mayo Clinic, and informed written consent was obtained from each patient. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
Patients participated in this study during a 3-day inpatient protocol in the clinical research unit, as previously described. 24 During this time, dietary sodium intake was maintained at 150 mEq/d; protein levels (in 24-hour collection of freely voided urine) and serum creatinine were measured on the first day of the inpatient protocol. BP was measured using automated oscillometric recording, and estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation. 25 On the second day, blood oxygen level-dependent (BOLD) magnetic resonance imaging scanning was performed on a Twin Speed Signa EXCITE 3.0T system (GE Medical Systems, Waukesha, WI) using a 12-channel torso phased array coil. 26 On the third day of the protocol, renal blood flow (RBF) was measured using multidetector CT, and blood samples were collected from the inferior vena cava and both renal veins.
All patients received antihypertensive drugs that block the renin-angiotensin system (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). RVH patients subsequently underwent renal stenting, or continued standard medical therapy, according to clinical indications and management decisions (including resistant hypertension or progressive decline in renal function). Eighteen RVH patients (9 medically treated and 9 stented after standard procedures) returned for repeat measurements 3 months later. Of the 24 patients with RVH, 7 patients underwent transjugular renal biopsy during renal vein blood collection, and 5 mm sections subsequently stained with hematoxylin and eosin and trichrome.
Tissue Oxygenation Determined by BOLD Magnetic Resonance Imaging
Renal oxygenation was detected using R 2 * maps using BOLD magnetic resonance imaging, and intrarenal hypoxia expressed as R 2 *, an index of deoxyhemoglobin concentration in the kidney. 26 Scans were performed under suspended respiration, consisting of a 2-dimensional fast spoiled gradient echo sequence with multiple echo times, as previously described. 27 Analysis of BOLD data from axial images was performed in regions of interest traced through the midpole hilar region of each kidney on T2*-weighted images, which were then transferred to the corresponding R 2 * parametric image. Then, BOLDdependent magnetic resonance imaging data were processed using Matlab 7.10 (The Math Works, Natick, MA). To determine the fraction of the kidney area in which tissue hypoxia was present (fractional tissue hypoxia), we measured the percentage of voxels from the whole-kidney regions of interest with R 2 * values >30/s averaging all available slices, as described previously.
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Blood Sampling and Measurement of RBF
To measure single-kidney RBF, on the third day of the inpatient protocol, the common femoral vein was cannulated. First, blood samples were selectively collected from the inferior vena cava and the right and left renal veins with 5F pigtail Cobra catheter (Cook, Inc, Bloomington, IN). The catheter was then moved to the right atrium for central venous injection of contrast media for flow studies using multidetector CT. Multidetector CT imaging was performed using a dual source 64-slices helical scanner (SOMATOM Definition, Siemens Medical Solution, Forchheim, Germany) after a bolus injection of iopamidol 370 (0.5 mL/kg), as described previously. 29 Kidney volume (5-mm-thick slices) was assessed in the helical mode after a second similar contrast injection to determine both cortical and medullary volumes. Multidetector CT images were analyzed using the ANALYZE (Biomedical Imaging Resource Center, Mayo Clinic, Rochester, MN). Regions of interest were selected from the aorta, renal cortex, and medulla of both kidneys. Average tissue attenuation was plotted versus time and the curves were fitted by algorithms to calculate hemodynamics in cortical and medullary regions of the kidney. Single-kidney RBF was calculated by multiplying kidney volume (cc tissue) by renal perfusion (mL/min per cc tissue), as previously described. 30 In HVs, blood samples from a peripheral (antecubital) vein and a spot urine sample were collected during a single visit, and dietary sodium intake was not regulated.
EMPs Isolation and Analysis
EVs were isolated from whole urine using Total Exosome Isolation reagent (Invitrogen, Waltham, MA) according to the manufacturer's guidelines. Urine samples (1000 μL) were centrifuged at 2000g for 30 minutes at 4°C to remove cells and debris. Supernatants (800 μL) were mixed with 1 volume of the Total Exosome Isolation reagent and incubated for 1 hour at room temperature. After incubation, samples were centrifuged at 10 000g for 1 hour at 4°C. Pelleted exosomes were resuspended in EV buffer (2 mol/L sucrose and 500 mmol/L MES [2-(N-morpholino) ethanesulfonic acid, 4-morpholineethanesulfonic acid] solution). Isolated EMPs were stained for 2 hours at 37°C with 0.5 mmol/L Tag-it violet (Biolegend) cell labeling solution. Labeled EMPs were stained with cell-specific antibodies, including PL-VAP (LSBio), CD31 (Biolegend), and CD144 (Biolegend). EMPs were quantified using a FlowSight (Amnis, Seattle, WA) imaging flow cytometry, as previously described, 31, 32 by acquiring at least 50 000 Tag-it violet-positive events. EMPs were measured using flow-gating strategy including a first positive gate for Tag-it violet events followed by positive gate for PL-VAP and positive or negative gate for other antibodies, and their combination evaluated for relationship with renal parameters. Acquisition was performed using Image StreamX Imaging Flow Cytometer (Amnis Corporation, Seattle, WA) equipped with INSPIRE software. The level of EMPs was expressed as a percentage.
Histological Analyses
Capillary density was quantitated on hematoxylin and eosin-stained slides by counting the total number of PTC enclosed within 10 random 0.25-mm 2 fields (each of which was delineated by a 1-cm 2 ocular grid viewed at 400 magnification) and expressed as mean per field. Capillaries were identified by the presence of lumen, red blood cells, and an endothelial cell lining. 33 The degree of fibrosis in the renal cortex and medulla was semiautomatically quantified in trichrome-stained slides in 10 to 15 fields using a masking algorithm based on color thresholding and edge detection in AxioVisionc (Carl Zeiss MicroImaging) and expressed as an average of percent fibrosis to total field area.
Statistical Analyses
Data were analyzed using the JMP software package version 10.0 (SAS institute, Cary, NC). Normally distributed data were expressed as mean±SD and non-normally distributed data as median (range). Comparisons among the HVs, EH, and RVH groups were performed using ANOVA followed by an unpaired 2-tailed t test (or the Wilcoxon rank-sum test for skewed data) and correlation coefficients using least-square fit. Spearman rank correlation analysis was used to test for association between EMPs and other variables. The stenotic kidney in RVH was compared with the average of the left and right kidneys in EH patients. Comparisons between individual kidneys before and after treatment and changes over time in the 2 treatments groups were performed using paired t test. P≤0.5 was considered statistically significant.
Results
Patient Characteristics
The characteristics of the 52 study participants are presented in the Table. There were no clinical differences among the groups, except for BP and renal function. Mean arterial pressure (MAP) of EH and RVH patients was higher compared with those in HVs (P=0.025 and P=0.003, respectively), whereas eGFR of EH and RVH patients was lower (P=0.008 and P<0.001, respectively). RBF and cortical perfusion in stenotic kidneys of patients with RVH were lower than in kidneys of EH patients (P<0.001 and P<0.001, respectively). Renal tissue hypoxia levels, defined by both R 2 * and fractional hypoxia (R 2 *>30/s), were higher in RVH than in EH kidneys (Table; Figure 1B ).
PTCs-EMPs Levels in Hypertensive Patients
There was no difference among the patient groups in levels of plasma or urinary PL-VAP (Figure 2A ). However, urinary levels of PL-VAP + /CD31 − /CD144 − EVs were elevated in EH and RVH compared with HV subjects (P<0.001 and P=0.001, respectively), as shown in both intensity graphs and representative fluorescent images ( Figure 2B and 2C ). These were considered to represent PTC-EMPs. Renal and systemic venous levels were not different among the groups.
Among all participants, urinary PTC-EMPs levels correlated directly with MAP and inversely with eGFR but not with proteinuria ( Figure 3A and 3B ). In addition, in RVH patients, PTC-EMPs showed inverse correlation with stenotic RBF and cortical perfusion and direct correlation with single stenotic kidney R 2 * and fractional hypoxia ( Figure 3C-3E ).
Correlation Between PTC-EMPs Levels and Histological Findings
Similar to the entire RVH study population, a negative correlation was observed within the 7 biopsied RVH patients between urinary PTC-EMPs levels and RBF and cortical perfusion of the stenotic kidney (spearman correlation=−0.785, P=0.036, spearman correlation=−0.787, P=0.036, respectively). Furthermore, urinary PTC-EMPs levels were inversely correlated with the number of PTC and directly with interstitial fibrosis (Figure 4) . No correlations were observed between histological findings and any other EV levels, including PLVAP 
Change in PTC-EMPs Levels With Treatment
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In repeated measurements of urinary PTC-EMPs in RVH patients 3 months after stenting (n=9) or continued medical therapy (n=9), the change in urinary PTC-EMPs levels was not significant in either group compared with baseline ( Figure 5A and 5B) and was not significantly different between them (−10.44 versus −2.93; P=0.15). However, we observed a significant inverse correlation between the changes in urinary PTC-EMPs level and renal function (spearman correlation=−0.582; P=0.011; Figure 5C ).
Discussion
This study demonstrates that urinary levels of PTC-EMPs, assessed using flow cytometry, are elevated in hypertensive patients compared with HVs and in patients with RVH are correlated with histological findings and clinical parameters, such as MAP, eGFR, RBF, cortical perfusion, and tissue hypoxia of the stenotic kidney. Because sustained endothelial activation and cellular injury may lead to release of EMPs in the urine, 4 we interpret these results as indicating that urinary PTC-EMPs may reflect renal microvascular capillary injury in hypertensive patients.
Hypertension is an important cause of CKD, and evolution of hypertensive kidney injury may involve PTC damage. 34 Possibly, detection of PTC injury at the early phase of hypertension might direct management decisions. PTC rarefaction, along with interstitial fibrosis and tubular atrophy, is one of the major hallmarks of CKD and predicts renal outcome in these patients. [1] [2] [3] In response to kidney injury, endothelial cells of PTC may initially proliferate and subsequently dropout. 35 Such capillary loss typically precedes development of prominent tubulointerstitial fibrosis. 36, 37 In addition, a loss of postglomerular capillaries leads to a reduction in oxygen supply, which is one of the common pathways of CKD. 38 EVs detected in urine might be released from different cell types along the renal nephron and urinary tract. 6 Such EV release is because of cellular activation and cell stress, which induce shedding from plasma membrane of EV, called micropartilces. 39, 40 For example, Burger et al 41 showed that urinary podocyte-derived microparticles are generated by exposure to mechanical stretch and high glucose and may reflect early glomerular injury in diabetic nephropathy. Circulating EMPs are also increased in hypertension, diabetes mellitus, and CKD. 40 Therefore, analysis of urinary EVs bearing renal cellular markers may be useful to probe the status of kidney cells without need for invasive renal biopsy. However, EVs that reflect the status of PTC have not been identified.
In the present study, to measure PTC-EMPs, we compared several endothelial cell markers, including PL-VAP, CD31, and CD144. Interestingly, we found that urinary PL-VAP + /CD31 − /CD144 − EMPs levels were higher in hypertensive patients compared with HVs and correlated with both clinical and histological parameters. There are several possible reasons for the closer association of CD31 − and CD144 − with PTC injury. First, besides endothelial cells, CD31 is also expressed on the surface of platelets, neutrophils, and lymphocytes. 14, [18] [19] [20] Second, compared with endothelial cells in the glomeruli, arteries, and venules, the expression of CD31 is lower in PTC and might therefore constitute a less robust marker of PTC. 42 Third, CD144, or vascular endothelial-cadherin, is expressed on endothelial cells and functions as a gatekeeper of endothelial junction but is also expressed on hematopoietic stem cells. 20 Furthermore, loss of CD144 expression may indicate endothelial cells that have lost their permeability barrier or have transitioned to mesenchymal cells. 43, 44 Notably, CD144 expression is relatively weak or absent in extraglomerular vessels. 45 Consequently, urinary PL-VAP + /CD31 − /CD144 − EMPs are likely released from and may reflect PTC injury. Indeed, their urinary levels correlated well with renal function. Vascular occlusion in patients with renal artery stenosis reduces blood flow and GFR. 46, 47 Subsequently, stenotic lesions not only induce hypoxia in the kidney, as observed in this study, but also activate the renin-angiotensin-aldosterone system and evoke oxidative stress, inflammation, and microvascular rarefaction. 48, 49 In this study, urinary PTC-EMPs levels were inversely correlated with RBF and cortical perfusion of stenotic kidney. Importantly, significant correlation between urinary PTC-EMPs and histological findings of capillary rarefaction was also observed. The significant inverse correlation between a fall in urinary PTC-EMP concentration and an increase in eGFR after revascularization further underscores the potential functional significance of this measure. Contrarily, proteinuria was not correlated with urinary PTC-EMPs in this study, possibly because the proteinuria of our study groups was within a normal range. Thus, urinary PTC-EMPs levels in hypertension might provide an early marker of renal injury independent of proteinuria.
There are currently no biomarkers reflecting PTC injury in RVH. In the present study, although there was no change urinary PTC-EMPs level after treatment, we observed a significant inverse correlation between the changes in urinary PTCEMPs level and renal function. Notably, some of our patients had unilateral disease or asymmetrical bilateral disease but only the more severely stenotic kidney was revascularized. Therefore, the contralateral (nonstenotic or less stenotic) kidney could have masked differences in absolute numbers of EMP among the groups. These differences might have been better captured by paired changes in urinary PTC-EMPs level within patients. Furthermore, PTC-EMPs might be more useful as biomarkers in patients with CKD in whom both kidneys are similarly injured or treated. Thus, we think that urinary PTC-EMPs could serve as biomarkers reflecting PTC injury and renal function although additional and larger studies are needed to address this point.
Interestingly, renal vein and systemic PTC-EMPs levels were not different among the groups in this study, probably because most EVs found in the urine originate from genitourinary tract rather than systemic blood. 6, 50 Because PL-VAP is expressed in the vascular endothelium of other organs, 21 the renal vein and systemic PTC-EMPs might not reflect specifically renal PTC injury. Therefore, urinary EVs may serve as a more sensitive biomarker than systemic EVs to reflect renal injury.
EV isolation presents an important technical challenge. We used a commercial isolation kit, which is relatively quick and does not require laborious ultracentrifugation or large urine volumes, which might be impractical in the clinical setting. 51, 52 However, the cost of isolation kits is not insignificant, especially when applied to a large number of samples. 52 Another potential confounder is proteinuria that can interfere with detection of urinary EV protein, owing to exosome-like particle of albumin-containing solution. 53 However, urinary protein levels were unaltered in our patients. In addition, EVs loss from the sample might occur during sample processing. Therefore, we expressed PTC-EMPs as a fraction of total EV count. Indeed, longitudinal measurement of PTC-EMPs levels in medically treated RVH patients demonstrated the reproducibility of our approach.
Our study has some limitations. First, this study has a relatively modest sample size, and the numbers of patients who underwent renal biopsy or revascularization were small. Thus, larger studies are needed to confirm our results. Second, urinary PTC-EMPs also might originate from the bladder epithelium, which expresses low level of PL-VAP mRNA. 21 Third, inhibitors of the renin-angiotensin system may modulate urinary levels of PTC-EMPs in hypertensive patients, by either increasing 54 or decreasing PTC loss. Finally, urine samples from HVs were obtained in untimed collection. Although useful to assess proteinuria, their compatibility to timed urine collection is limited. In addition, for ethical reasons, blood was collected from a peripheral vein in HVs.
In conclusion, we observed elevated urinary levels of PTC-EMPs in hypertensive patients compared with HVs. PTC-EMPs might be useful markers reflecting capillary rarefaction in hypertension and may enable noninvasive monitoring of the renal microcirculation and the success of therapeutic strategies. Future studies are needed to evaluate their levels in other diseases and their utility for monitoring success of therapy.
Perspectives
PTC rarefaction is one of the major hallmarks of CKD and predicts renal outcome in CKD patients. EVs are membrane-bound vesicles produced and released by cells. Urinary EVs have gained important recognition as potential diagnostic biomarkers in renal disease. However, EVs reflecting PTC injury have not been identified. This article describes the characterization of an EMPs reflecting PTC loss in hypertensive patients. Compared with healthy controls, urinary PTC-EMPs levels were elevated in hypertensive patients and correlated directly with BP and inversely with renal function. Furthermore, urinary PTC-EMPs levels correlated directly with renal histological PTC count and fibrosis. Urinary PTC-EMPs may be useful as novel biomarkers of intrarenal capillary loss.
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